Navigation Links
IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
Date:2/4/2008

either destroy cancer cells by activating the immune system or prevent tumor recurrence by triggering a specific adaptive immune response. IDM Pharma is dedicated to maximizing the full therapeutic and commercial potential of each of its innovative products to address the needs of patients and the physicians who treat these patients.

For more information about the company and its products, visit http://www.idm-pharma.com.

Forward-Looking Statements

This press release includes forward-looking statements that reflect management's current views of future events including statements regarding the significance of COG's findings that L-MTP-PE, in combination with chemotherapy, has demonstrated a significant long-term overall survival advantage based on long-term patient follow-up, the effect such findings may have on the Company's ability to obtain regulatory approval of L-MTP-PE in Europe and the United States, the pathway to a potential positive opinion from the CHMP based on the CHMP's non-binding opinion regarding the clinical benefit in survival of L-MTP-PE, the Company's plans to address the remaining questions with respect to the MAA during the time extension or clock-stop granted by the CHMP, and the expected timing of a final opinion from the CHMP and of a final regulatory decision regarding the MAA in the European Union, as well as the Company's plans to collect, analyze and submit additional Phase 3 data in an amended NDA for L-MTP-PE and to respond to other matters raised by the FDA and timing for preparation of the NDA amendment. Actual results may differ materially from the forward-looking statements due to a number of important factors, including, but not limited to, whether the Company will be able to provide assurance regarding the quality of the existing data and to respond to the remaining issues with regard to the MAA, including verification of data quality and chemistry, manufa
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015  Mallinckrodt plc (NYSE: MNK ) announced ... share repurchase program. The open-ended authorization permits the company ... ordinary shares. "Funding additional initiatives and ... we continue to pursue a range of focused growth ...
(Date:1/23/2015)... Jan. 23, 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... in the development and sale of patented biopharmaceutical medicine, ... pharmaceutical ingredients (API) today announced the business and development ... 1. Following the September 2014 JCM application ...
(Date:1/22/2015)... MINNEAPOLIS, Jan. 22, 2015  Uroplasty, Inc. (NASDAQ: UPI ... markets innovative proprietary products to treat voiding dysfunctions, today ... ended December 31, 2014.  Global revenue for the ... $4.4 million, a new quarterly revenue record, as compared ...
Breaking Medicine Technology:Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18
... EXTON, Pa., Aug. 18, 2011 Kensey Nash Corporation (NASDAQ: ... on regenerative medicine for a wide range of medical procedures, ... year ended June 30, 2011.   Fourth ... earnings per share of $0.34, which includes net Norian acquisition ...
... MEDFORD, N.Y., Aug. 18, 2011 Richard Larkin, Chief Financial ... develops, manufactures, markets and licenses point-of-care diagnostic tests, is among ... from Long Island Business News ( LIBN ). ... year.  Among the honorees, Mr. Larkin was one of two ...
Cached Medicine Technology:Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 2Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 3Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 4Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 5Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 6Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 7Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 8Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 9Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 10Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 11Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 12Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 13Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 14Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 15Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 16Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 17Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 18Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 19Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 20Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 21Chembio Diagnostics' CFO Richard J. Larkin Among the Recipients of "2011 CFO of the Year" Award from Long Island Business News 2Chembio Diagnostics' CFO Richard J. Larkin Among the Recipients of "2011 CFO of the Year" Award from Long Island Business News 3
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved television ... 32nd Annual Miami Breast Cancer Conference planned ... (PER®) , shares that “a fast-growing, virulent” cancer in ... had not followed up her clean mammogram with an ...
(Date:1/22/2015)... 2015 Yesterday, Senator Holly Mitchell ... Kristin Olsen (R-Modesto) were honored by the California ... biotechnology, biomedical science, medical device and pharmaceutical innovation ... the “2014 Life Sciences Champion” award from CHI ...
(Date:1/22/2015)... 2015 IsoComforter, Inc. has introduced the most ... IsoTube design to treat specific body parts and muscle groups. ... and easy to use patented cold therapy machine with the ... orthopedic and muscle injuries. IsoComforter has become the industry ...
(Date:1/22/2015)... Payday lending practices in four southern ... financial distress to the states that permit them, according ... Center on Race and Wealth. , While they generate ... loans at the same time substantially depress economic activity, ...
(Date:1/22/2015)... As interest in the value of spiritual ... worldwide, Rev. Eric J. Hall , president and CEO ... will be the keynote speaker on January 27 at an ... system. , The conference, “Hope and Resilience: Innovative and Interdisciplinary ...
Breaking Medicine News(10 mins):Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3
... and don't know why? ,You could have sinusitis, one ... the conclusion of new research out of Georgetown University ... of Internal Medicine. Dr. Alexander Chester, an internist at ... patients and found that those who reported unexplained chronic ...
... class of antidepressant drugs could make heart patients less ... on Monday. Drugs called selective serotonin reuptake inhibitors (SSRIs), ... and less likely to clot, they found. ,The ... web sites)'s journal Circulation, suggests that doctors //should check ...
... public health concern. Poor fitness and low cardiorespiratory ... hypertension. Now a new study finds low cardiorespiratory ... ,Cardiorespiratory fitness level is measured by the maximum ... Research Institute of Public Health and the Kuopio ...
... that helps brain cells function normally also protects against ... lead to better treatments for the illness. ,Brain ... but researchers in the United States, who identified it ... of protein in the brain which are a characteristic ...
... of coronary heart disease in healthy women, and it ... to two studies released yesterday. ,The studies, published in ... of Medicine, expand on the discouraging results of previous ... //to help combat heart disease. ,This study and ...
... Hopkins University surgeons performed three simultaneous kidney transplants in ... rushing organs in labeled coolers among six operating rooms. ... us," said one of the recipients.,The six synchronized operations ... them -- became possible after an extraordinarily lucky,// six-way ...
Cached Medicine News:
... Eliminate the need for makeshift, modified nebulizer ... waste time gathering parts when your patient ... to deliver the utmost in Heliox rescue ... is fast becoming the standard of care ...
... spill-proof design and effective output, even when ... medical nebulizers are free-standing for easy preparation., ... available., ,All Portex® medication nebulizer products ... feature consistently fine misting and the efficient ...
... spill-proof design and effective output, even when ... medical nebulizers are free-standing for easy preparation., ... available., ,All Portex® medication nebulizer products ... feature consistently fine misting and the efficient ...
... as well as humidification, try Flo-Mist™., ... volume, continuous medication nebulizer (CMN), engineered to ... 200 ml reservoir and jet flow design ... nebulized medication delivery at 25 ml/hr. Particles ...
Medicine Products: